Travoprost Intraocular

NCT06066645 is a Glaukos-sponsored Phase 4 trial pairing iDose TR, their FDA-approved sustained-release travoprost intracameral implant, with the iStent Infinite trabecular bypass device in patients with elevated intraocular pressure [1]. The study tests whether combining a drug-eluting intracameral implant (inserted into the anterior chamber of the eye) with a minimally invasive glaucoma surgery (MIGS) device delivers additive IOP lowering versus either approach alone. For Glaukos (GKOS), this is a franchise-building exercise: both products are theirs, and demonstrating a durable combination benefit would support bundled selling into the growing MIGS-plus-pharmacotherapy segment. The real pipeline risk sits elsewhere in their program, specifically the second-generation implant iDose TREX, now in a Phase 2b/3 program (NCT07075718) designed to extend dosing duration beyond the current product's roughly three-year ceiling [2].

iDose TR itself is not an investigational compound. The FDA approved travoprost intracameral implant in December 2023 for reduction of IOP in patients with open-angle glaucoma or ocular hypertension, based on pooled data from two Phase 3 trials (NCT03519386 and NCT03868124) [3][4][5]. The approval covered a single-administration implant inserted into the anterior chamber, releasing travoprost over months to years. NCT06066645, registered as a Phase 4 study of 150 patients with estimated primary completion in May 2027, is a post-marketing combination study with iStent Infinite rather than a registration trial [1]. The node's internal phase=3 label reflects a database categorization, not the trial record. The forward-looking readout investors should track is the second-generation implant iDose TREX (NCT07075718), a combined Phase 2b/3 program evaluating a device of similar form factor but with roughly twice the drug capacity, aimed at extending IOP-lowering duration [2].

Travoprost is a prostaglandin F2α analog. It binds the FP receptor (gene PTGFR), a G-protein-coupled receptor expressed in the ciliary muscle and uveoscleral outflow tissues of the eye [6]. Activating that receptor relaxes the ciliary muscle and remodels extracellular matrix in a secondary drainage pathway called the uveoscleral route, letting aqueous humor leave the eye faster and dropping intraocular pressure. Critically, the dominant IOP-lowering effect of prostaglandins is via the uveoscleral pathway, not via the trabecular meshwork, which is the eye's primary drainage filter. That distinction matters here: iStent Infinite is a trabecular bypass device (a tiny titanium stent placed through the trabecular meshwork to restore flow through the main drainage route), so the two mechanisms are physiologically additive rather than redundant. The biological rationale for the combination is sound. The pharmacology itself is as well-validated as any in ophthalmology: topical prostaglandin analogs (latanoprost, bimatoprost, travoprost eye drops) have been first-line glaucoma therapy for more than two decades. The twist here is drug delivery, not pharmacology. Daily eye drops have a well-documented adherence problem: patients forget, bottles run out, elderly patients struggle with instillation. An intracameral implant replaces the drop with a slow-release depot that sits inside the eye and dispenses drug for months to years, taking the patient out of the compliance loop. PTGFR has strong disease association for open-angle glaucoma and ocular hypertension, consistent with multiple approved drugs validating the biology [7].

NCT06066645 is a multicenter, randomized, double-masked trial enrolling adult patients with elevated IOP who receive the iStent Infinite trabecular bypass system, then randomizes them to the travoprost intracameral implant on top of iStent versus iStent alone [1]. Primary endpoint is change from baseline in mean diurnal IOP. Target enrollment is 150, sponsor is Glaukos Corporation, status is recruiting, estimated primary completion May 2027. For anchoring: in the pivotal GC-010 and GC-012 Phase 3 trials, patients entered at baseline mean diurnal IOP near 24 mmHg, and the slow-release iDose TR arm produced 6.6 to 8.5 mmHg reductions over the first 3 months, non-inferior to twice-daily topical timolol, with roughly 81% of eyes remaining IOP-medication-free at 12 months [4][11]. That is the commercial pitch, and this Phase 4 trial extends the evidence into a MIGS-combined population Glaukos is actively selling into. Design concerns: without a sham or placebo arm matched to the implant procedure, the add-on effect can be measured against baseline but comparison to drops-plus-iStent is harder. The relevant question for payers is not whether adding iDose TR lowers IOP, which it should given the pivotal data, but whether the combination offers meaningful advantage over the cheaper option of iStent plus generic prostaglandin drops.

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 59%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by the sponsor's thin or weak approval record, its few secondary endpoints, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Four distinct risk categories. First, efficacy ceiling: pairing two IOP-lowering interventions in patients already stabilized on one risks a smaller incremental benefit than either alone, and the trial could hit statistical significance without clinical meaningfulness. Second, device-related safety, specifically corneal endothelial cell loss. The iDose TR label notes endothelial cell density decreases, and the ongoing commercial reality is that any additional intracameral manipulation (iStent placement, implant insertion) compounds that risk. Pooled Phase 3 safety data showed the first-generation implant generally well-tolerated through long-term follow-up [4], but combination data in a MIGS-pretreated population is thinner. Third, competitive risk: Durysta (bimatoprost intracameral implant, AbbVie, FDA-approved March 2020) is the only other approved sustained-release intracameral prostaglandin and the most direct modality competitor [9]. Durysta is biodegradable with a 90-day release window (though some patients see effect up to two years) and is restricted to a single implant per eye due to endothelial cell concerns. iDose TR differentiates on longer dosing duration (2 to 3 years per device) and a non-biodegradable, surgically anchored design, but Durysta remains the fallback option for phakic patients and for patients whose trabecular meshwork has already been disrupted by prior MIGS. Fourth, commercial risk even on a successful readout: payers already push back on MIGS-plus-sustained-release pricing, and demonstrating statistical benefit may not translate to coverage policy change if generic prostaglandin drops plus iStent remain the budget-friendly path. Glaukos' broader risk is pipeline concentration: iDose TREX readouts are the near-term valuation driver, and a miss there would hit harder than any outcome from this specific combination study [2].

Noise relative to the signal elsewhere in Glaukos' pipeline. This specific combination study extends an evidence base rather than opening a new one, and a positive readout would support marketing claims without changing the drug's regulatory status. The signal to watch is NCT07075718, the Phase 2b/3 program for the second-generation iDose TREX implant, which addresses the duration limitation of the first product and is the clearest path to a next commercial inflection for the sustained-release franchise [2]. Early TREX data presented at AGS 2026 showed a 9.4 mmHg IOP reduction at six weeks in the first patients, directionally consistent with the first-generation profile [2]. Check Glaukos' quarterly earnings for iDose TR commercial trajectory and management commentary on TREX timelines [10]. For investors modeling GKOS, patent expiry and exclusivity timelines, along with real-world uptake numbers from the company's reports, matter more than this particular trial's primary endpoint.